Skip to main content
. 2022 Jan 6;11:777587. doi: 10.3389/fonc.2021.777587

Figure 5.

Figure 5

Combination of venetoclax and inhibition of Mcl-1 induces apoptosis in trisomy 12 chronic lymphocytic leukemia (CLL) cells. (A) Diagram shows the percentage of survival in CLL cells transfected with scramble or Notch2 siRNA in the presence of treatment with venetoclax for 24 h (*p < 0.05, **p < 0.01). (B) Immunoblots show the level of Notch2, Mcl-1 in one representative CLL patient harboring trisomy 12 during treatment with venetoclax after transfection with either scramble control or Notch2 siRNA (*p < 0.05, **p < 0.01). (C) Bar diagrams depict the densitometric quantification of Notch2 and Mcl-1 in CLL cells harboring trisomy 12 transfected with scramble or Notch2 siRNA either in combination or not with venetoclax (*p < 0.05, **p < 0.01). (D) Trisomy 12 CLL cells were either treated with dimethyl sulfoxide (DMSO) or treated with 0.1 or 1 nM venetoclax, 100 and 300 nM AMG-176, or a combination of both for 48 h. Bar diagrams show the viability (%) in each condition measured by flow cytometry (*p < 0.05, **p < 0.01).